AstraZeneca

News

AZ closes on FDA verdict on tremelimumab in liver cancer

AstraZeneca's anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results.

News

FDA starts speedy review of Enhertu in lung cancer

AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its

News

GSK goes for gold as FDA starts review of daprodustat

GlaxoSmithKline says the FDA has started its review of daprodustat for anaemia associated with chronic kidney disease (CKD), as it strives to succeed where two other rivals in the HIF-PHI c

News

Seagen wins Enhertu patent dispute with Daiichi Sankyo

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages.

News

FDA restricts GSK's Xevudy due to lower efficacy against BA....

GlaxoSmithKline and Vir's Xevudy has become the latest COVID-19 antibody therapy to have its use restricted by the FDA as a result of waning activity against new variants of the virus.

News

AZ expands digital health plans with Huma alliance

AstraZeneca has bought a stake in digital health firm Huma Therapeutics in a deal that will see ownership of AZ's AMAZE disease management platform transfer to the UK startup.

AZ closes on FDA verdict on tremelimumab in liver cancer

FDA starts speedy review of Enhertu in lung cancer

GSK goes for gold as FDA starts review of daprodustat

Seagen wins Enhertu patent dispute with Daiichi Sankyo

FDA restricts GSK's Xevudy due to lower efficacy against BA....

AZ expands digital health plans with Huma alliance

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks